Agilon Health, Inc. 8-K Summary
Business Context and Reporting Period
Agilon Health, Inc. filed a Form 8-K dated February 17, 2023, with the report signed on February 22, 2023. The filing reports a board appointment under Item 5.02 and does not provide quarterly or annual financial results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Diana L. McKenzie was appointed to the Board of Directors effective February 17, 2023, as a Class II director.
- Her term expires at the Company’s 2023 annual meeting of stockholders.
- Ms. McKenzie was also appointed to the Audit Committee and the Compensation and Human Capital Committee.
Management Commentary, Risks, and Unusual Items
- The filing states that there was no arrangement or understanding between Ms. McKenzie and any other person regarding her selection as a director.
- Ms. McKenzie has more than 30 years of technology leadership experience, including serving as Workday’s first Chief Information Officer and holding technology leadership roles at Amgen and Eli Lilly.
- She currently serves on the boards of MetLife, Vertex Pharmaceuticals, and Paradox, and as a special advisor to Brighton Park Capital.
- No reportable related-party transactions were disclosed other than previously disclosed indemnification arrangements with directors.
- Ms. McKenzie will receive compensation under the Company’s previously disclosed non-employee director compensation programs.
Important Facts to Verify
- Confirm Ms. McKenzie’s committee assignments and service term through the 2023 annual meeting.
- Review the Company’s previously disclosed non-employee director compensation program for the applicable compensation terms.
- Review subsequent filings for any changes to board composition, committee membership, or director compensation.